Fundraising Fox
Delpor
Founded 2009 · 5 employees on LinkedIn · 3 known investors
Find your way into Delpor
Sign up to see every warm intro you have to Delpor
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Delpor team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Delpor develops subcutaneous implant devices that deliver therapeutic drugs over extended periods (6-12 months) for chronic condition treatment. The company's passive implant technology enables sustained-release drug delivery through simple in-office procedures, targeting improved patient adherence and consistent pharmacokinetic profiles.
Investors · 3
How we know: CloudStone Capital's portfolio page · Not right? Tell us
Non-dilutive funding · 8 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $224.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $224.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $222.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $344.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Delpor do?
- Delpor develops subcutaneous implant devices that deliver therapeutic drugs over extended periods (6-12 months) for chronic condition treatment. The company's passive implant technology enables sustained-release drug delivery through simple in-office procedures, targeting improved patient adherence and consistent pharmacokinetic profiles.
- Who are Delpor's investors?
- Delpor's investors include CloudStone Capital, Kairos Venture Investments, Llc, Ulu Ventures.